These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18801601)

  • 1. [Paroxysmal nocturnal hemoglobinuria].
    Geffray L
    Rev Med Interne; 2008 Nov; 29(11):957-61. PubMed ID: 18801601
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
    Guasch A
    Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
    [No Abstract]   [Full Text] [Related]  

  • 3. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia.
    Brodsky RA
    Ann Intern Med; 2008 Apr; 148(8):587-95. PubMed ID: 18413620
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Hill A
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):849-50. PubMed ID: 16491626
    [No Abstract]   [Full Text] [Related]  

  • 6. [C5: eculizumab].
    Miyamoto K
    Brain Nerve; 2014 Oct; 66(10):1191-9. PubMed ID: 25296873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
    Hill A; Rother RP; Hillmen P
    Haematologica; 2005 Dec; 90(12 Suppl):ECR40. PubMed ID: 16464755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria.
    Emadi A; Brodsky RA
    Am J Hematol; 2009 Oct; 84(10):699-701. PubMed ID: 19705437
    [No Abstract]   [Full Text] [Related]  

  • 9. Eculizumab in paroxysmal nocturnal hemoglobinuria.
    Takita M; Matsumura T; Kami M
    N Engl J Med; 2006 Dec; 355(26):2787; author reply 2787-8. PubMed ID: 17193722
    [No Abstract]   [Full Text] [Related]  

  • 10. [Successful eculizumab treatment for multiple coronary thrombosis complicated in paroxysmal nocturnal hemoglobinuria].
    Taniguchi A; Ikezoe T; Takeuchi A; Togitani K; Yoshimoto M; Tanioka K; Kitaoka H; Yokoyama A
    Rinsho Ketsueki; 2014 Aug; 55(8):965-9. PubMed ID: 25186487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A closer look at paroxysmal nocturnal hemoglobinuria.
    Rachidi S; Musallam KM; Taher AT
    Eur J Intern Med; 2010 Aug; 21(4):260-7. PubMed ID: 20603032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria.
    Knoll BM; Letendre L; Steensma DP
    Am J Hematol; 2008 Nov; 83(11):881-3. PubMed ID: 18756538
    [No Abstract]   [Full Text] [Related]  

  • 13. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab.
    Danilov AV; Smith H; Craigo S; Feeney DM; Relias V; Miller KB
    Leuk Res; 2009 Jun; 33(6):e4-5. PubMed ID: 18952283
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab.
    van Bijnen ST; van Rijn RS; Koljenovic S; te Boekhorst P; de Witte T; Muus P
    Br J Haematol; 2012 Jun; 157(6):762-3. PubMed ID: 22372429
    [No Abstract]   [Full Text] [Related]  

  • 15. [With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab].
    Algado JT; Luque R; Nuñez R; Sanchez B
    Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):109-10. PubMed ID: 22197277
    [No Abstract]   [Full Text] [Related]  

  • 16. Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure.
    Kelly RJ; Hill A; Arnold LM; Khursigara G; Kanagasundaram NS; Hillmen P
    Leuk Res; 2011 Apr; 35(4):560-2. PubMed ID: 21145109
    [No Abstract]   [Full Text] [Related]  

  • 17. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Hill A
    Clin Adv Hematol Oncol; 2008 Jul; 6(7):499-500. PubMed ID: 18654116
    [No Abstract]   [Full Text] [Related]  

  • 19. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
    Heitlinger E
    Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.